Alliance Pharma PLC Directorate Changes (8511L)

TIDMAPH

RNS Number : 8511L

Alliance Pharma PLC

18 May 2022

 
For immediate release  18 May 2022 
 

ALLIANCE PHARMA

("Alliance" or the "Group")

Directorate changes

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, in line with good corporate governance, David Cook, Alliance's Chair, will be stepping down next year, following the AGM in May 2023, after serving on the Board for nine years.

Jo LeCouilliard, currently a Non-Executive Director on the Board of Alliance, will become Chair following the AGM in May 2023.

Jo LeCouilliard joined Alliance as a Non-Executive Director on 1 January 2019. She brings over 25 years of international healthcare management experience through her career at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and the Asia Pacific Pharmaceuticals business. Jo is a Chartered Accountant and is currently a Non-Executive Director at Circassia Group plc, Indivior plc and Recordati S.p.a.

David Cook commented: "Alliance has developed significantly over the time I have been with the business, building an international footprint and transitioning to focus on consumer healthcare brands. I am confident that the Company has a bright future, led by an outstanding senior management team. Jo has been an invaluable Board member over the past three and a half years and we are delighted that she has agreed to chair the Board as the Company continues on its growth trajectory. I look forward to working closely with her during my remaining time at Alliance."

Jo LeCouilliard commented: "I am delighted to be taking on the position of Chair following next year's AGM. I have been really impressed by Alliance's strong management team and strategy over my last three and a half years on the Board. The Company has successfully executed a number of strategic consumer healthcare acquisitons and has built a solid international infrastructure. I look forward to leading the Board in taking the Company forward."

For further information:

 
Alliance Pharma plc                             + 44 (0)1249 466966 
Cora McCallum, Head of Investor Relations 
 & Corporate Communications                     + 44 (0)1249 705168 
[e-mail] 
 
                                                    + 44 (0)20 7466 
Buchanan                                                       5000 
Mark Court / Sophie Wills / Hannah Ratcliff 
[e-mail] 
 
                                                    + 44 (0)20 7260 
Numis Securities Limited                                       1000 
Nominated Adviser: Freddie Barnfield / Duncan 
 Monteith 
Corporate Broking: James Black 
 
                                                    + 44 (0)20 7597 
Investec Bank plc                                              5970 
Corporate Finance: Daniel Adams 
Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGPUWWAUPPGMM

(END) Dow Jones Newswires

May 18, 2022 10:07 ET (14:07 GMT)